TOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced that Bobby Gaspar, M.D., Ph.D., co-founder and chief executive officer, has been named to the inaugural 2024 TIME100 Health, an annual list recognizing the impact, innovation, and achievement of the world’s most influential individuals in health this year.

东京、伦敦和波士顿，2024年5月3日（环球通讯社）--Orchard Therapeutics最近被麒麟协和收购，目的是加速向全球患者提供新的基因疗法，今天宣布，联合创始人兼首席执行官博比·加斯帕（Bobby Gaspar）医学博士被提名为2024 TIME100 Health首届榜单，该年度榜单认可了今年世界上最有影响力的健康人士的影响、创新和成就。

The full list and related tributes will appear in the May 13, 2024 issue of TIME and is available online at https://time.com/collection/time100-health/. “I am incredibly humbled, privileged, and immensely proud to be included on this esteemed list of influential and accomplished people shaping the future of health care,” said Dr.

完整的名单和相关的贡献将出现在2024年5月13日的《时代》杂志上，可在网上查阅https://time.com/collection/time100-health/.“我非常谦卑，非常荣幸，也非常自豪能被列入这个令人尊敬的名单，名单上的有影响力和有成就的人塑造了医疗保健的未来，”博士说。

Gaspar. “While these accolades are often attributed to individuals, I truly believe this honor extends to the entire team at Orchard Therapeutics and our global network of clinical and academic collaborators. It is because of your collective efforts that we are transforming the treatment landscape for previously intractable diseases, and I share this recognition with all of you.” Dr.

加斯帕。“虽然这些荣誉往往归功于个人，但我真的相信这一荣誉延伸到了Orchard Therapeutics的整个团队以及我们的全球临床和学术合作者网络。正是由于你们的集体努力，我们正在改变以前难以治愈的疾病的治疗格局，我与你们所有人分享这一认可。”。

Gaspar is a world-renowned physician and scientist, as well as an accomplished executive with more than 30 years of experience in medicine and biotechnology. He has been a pioneer in the evolution of hematopoietic stem cell (HSC) gene therapy—bringing it from some of the first studies in patients into late-stage clinical trials, and ultimately through Orchard’s first regulatory approvals in Europe and the U.S., enabling the delivery of these potentially transformative medicines to eligible children.

加斯帕是世界著名的医生和科学家，也是一位有着30多年医学和生物技术经验的杰出高管。他一直是造血干细胞（HSC）基因治疗进化的先驱，将其从最初的一些患者研究带入晚期临床试验，并最终通过Orchard在欧洲和美国的首次监管批准，使这些潜在的转化药物能够提供给符合条件的儿童。

His unparalleled expertise and deep relationships with key physicians and treatment centers .

他无与伦比的专业知识以及与关键医生和治疗中心的深厚关系。